Biogen And Sage On Plans To Build A Brain Franchise Together
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
You may also be interested in...
The companies reported positive Phase III data in postpartum depression, a market opportunity of up to half a million women in the US with a condition that remains underdiagnosed.
Lecanemab is now filed for accelerated approval with the US FDA, but the wait for a Phase III readout could impact the hunt for Biogen’s next CEO.
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption